Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us



Clinical Trial Title

TARGeted Intraoperative radioTherapy Boost vs. Postoperative External Beam Radiotherapy boost

Trial Status

Open to Enrollment

Start Date

November 9, 2020


Trial Type

Cancer - Adult Oncology

Specific Condition

Breast Cancer


TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial.

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with breast cancer and suitable for conserving surgery and whole breast radiotherapy, with a histological confirmation of carcinoma can be included in the study once a written informed consent is obtained. All patients should be available for regular follow-up (according to local policies) for at least ten years.
  • Less than 46 years of age
  • More than 45 years of age and with one or more of the following poor prognostic factors:
  •  a) Grade 3
  •  b) ER and/or PgR negative
  •  c) lobular carcinoma
  •  d) extensive intraductal component (EIC)
  •  e) lymphovascular invasion
  •  f) axillary nodal involvement
  •  g) more than one tumour in the breast but still suitable for breast conserving surgery through a single specimen
  •  h) any factor or a combination of factors that puts the patient at a higher risk of local recurrence as per the current local guidelines : e.g., those who need a tumour bed boost or those not suitable for TARGIT-Alone as standard treatment.

Exclusion Criteria

  • Bilateral breast cancer at the time of diagnosis.
  • Patients with any severe concomitant disease that may limit their life expectancy
  • Previous history of malignant disease does not preclude entry if the expectation of relapsefree survival at 10 years is 90% or greater

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number

Central IRB

Principal Investigator Name

Mark Schray, MD

Contact Name

Oncology Clinical Research



Contact Fax


Contact E-Mail


Last Updated: Monday, November 30, 2020 03:24:46 PM